The RAPS store will be under maintenance Saturday, 17 April between 5 AM and 12 PM EST. Store functionality may be unavailable at times during this window.
We apologize for any inconvenience caused during this time.

Regulatory Focus™ > News Articles > Case Study: A Novel Investment Partnering Solution for Sharing Development Risk

Case Study: A Novel Investment Partnering Solution for Sharing Development Risk

Posted 01 December 2008

On 24 July 2008, on its earnings call, Eli Lilly and Company announced its intention to partner with TPG-Axon and NovaQuest for the development of Lilly's two lead molecules for the treatment of Alzheimer's disease.1 One molecule is a gamma-secretase small molecule and the other is an antibody targeted against A-beta. Both molecules are designed to modify the progression of mild to moderate Alzheimer's disease.

 

© 2021 Regulatory Affairs Professionals Society.

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe